Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world outcomes of younger patients with chronic lymphocytic leukemia treated with first-line BTK inhibitor or BCL2 inhibitor therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

HWH. WillisLFLindsey FitzgeraldHSHarsh Shah

Discussion

Loading...

Member takes

Overview

Observational study shows first-line BCL2i improves time to next treatment in younger chronic lymphocytic leukemia patients, hinting at long-term management benefits.

Key Points

  • Evaluate real-world outcomes of younger patients with chronic lymphocytic leukemia receiving first-line therapy with BTK inhibitors or BCL2 inhibitors.
  • Utilized the Flatiron Health electronic health record-derived database
  • Included patients under 55 years diagnosed with CLL receiving first-line therapy between 2015 and 2024
  • Compared outcomes of those treated with BTK inhibitors and BCL2 inhibitors using Kaplan-Meier and Cox regression analyses.
  • 426 patients included, with 78.2% receiving BTK inhibitors and 21.8% receiving BCL2 inhibitors
  • At 2 years, time to next treatment was significantly greater for BCL2i group (90.1%) compared to BTKi (70.8%)
  • Cox regression showed 1L BTKi associated with shorter time to next treatment compared to BCL2i (HR 3.84)

Cite This Study

Willis et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d564https://doi.org/10.1182/blood-2025-6316
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world comparison of time to next treatment for patients with high-risk CLL/SLL in first line of treatment.2024
  2. 2Frontline experience with second generation covalent Bruton tyrosine kinase inhibitors for mantle cell lymphoma: A single center experience2025
  3. 3Chemo ± immunotherapy remains utilized for chronic lymphocytic lymphoma in the real-world practice: Unmet needs, treatment patterns, and age disparities in the United States2025
  4. 4Efficacy and prognostic determinants of BTK inhibitors in chronic lymphocytic leukemia (CLL): A real-world single-center cohort study from China2025
  5. 5Real-world comparison of BTKi monotherapy and fixed-duration BTKi–Venetoclax for first line treatment of chronic lymphocytic leukemia patients without TP53 mutations or IGHV rearrangement2025